News

In this role, Paul will lead the company's global commercial strategy, drive business development initiatives, and play a pivotal role in fostering strategic partnerships. Paul Orange brings with him a wealth of experience in the bioprocessing industry, having held key leadership positions in various companies. His strategic vision, deep industry knowledge, and proven track record make him an excellent addition to the INFORS HT team. "We are delighted to welcome Paul to INFORS HT as our Chief Commercial Officer. His extensive experience and strategic insights will be instrumental in driving our commercial growth and strengthening our position as a global leader in bioprocess solutions," said Anja Hawrylenko, CHRO and representative of the shareholders in the board of directors. Before joining INFORS HT, Paul most recently served as Chief Commercial Officer & Board member at H.E.L Group. Throughout his career, he has demonstrated a strong commitment to innovation, customer satisfaction, and business excellence. Paul's leadership skills and passion for advancing bioprocessing technologies align seamlessly with INFORS HT's mission to empower researchers and bioprocess professionals with cutting-edge solutions. "I am thrilled to be joining INFORS HT, a company known for its commitment to innovation and excellence in the bioprocessing industry. I look forward to contributing to the continued success and growth of INFORS HT, and I am excited about the opportunities that lie ahead," commented Paul on his appointment. Paul holds a PhD in Molecular Neuroscience and a BSc. (Hons) in Anatomy & Cell Biology, both from The University of Sheffield. His commitment to continuous learning and staying at the forefront of industry trends reflects INFORS HT's dedication to providing state-of-the-art solutions to its customers. For more information about Paul Orange and his professional background, please visit his LinkedIn profile.

INFORS HT selected on 3rd place of the FOCUS-Business's Top 10 recommended midsize employers in Germany in the fields of research, development and science. Under the theme "Progress through Research" they focused on 6 central future fields of research and innovation policy, including modern technologies for a competitive, climate-neutral industry, clean energy generation and supply, sustainable mobility and a proactive, crisis-resistant, and modern healthcare systems that leverages opportunities of biotechnology and medicine. The Analysis comprised 36.000 companies employing between 11-500 people and 650.000 evaluations from employees. This recognition is reaffirmation that our current path aligns with success and our corporate values provide valuable benefits to our teams and collaborators. This underscores our commitment to fostering a positive and supportive work environment with fair compensation, flexible working arrangements and a culture of appreciation contributing to the overall satisfaction and well-being of our employees and to innovation in the biotechnology space. See the full list and find out more about the methodology used on the FOCUS Business list.

Celebrating Excellence in Entrepreneurship and Innovation. We are proud to announce we have been selected as one of the Top 5 finalists for the Swiss Venture Club Northern Switzerland Prize 2023. The Swiss Venture Club Prize is renowned for celebrating the most innovative and forward-thinking companies and entrepreneurs in the region. We are honored to be among the finalists and thank all our colleagues, partners and stakeholders for their continuous support in working towards our mission of improving our customers' bioprocess-workflows. For more details about the competition and to learn about the other remarkable finalists, please visit here.

2023 is a big year for stainless steel bioreactors at INFORS HT. We kicked off the year with the inauguration of the new Techfors-S production line. Through the scaleup of our capabilities in this state-of-the-art facility, we are best equipped to continue meeting the increasing demand from #biopharma and biotech for stainlesssteel bioreactors.

Dr Susanne Braum will join INFORS HT as the Managing Director for its German subsidiary Infors GmbH. Susanne is a expert in medical and laboratory systems for the international life science industry and her appointment will further strengthen the capability of INFORS HT to serve its German customers. Dr Susanne Braum will take-over the overall business responsibility for INFORS HT activities in Germany. She will play an important role in enhancing the group’s market position in this key market. Susanne joins INFORS HT with more than 20 years of experience in the international marketing & sales of medical and laboratory systems and life science applications as well as market and business development programmes. Her capacity to foster solid co-operations and partnerships with customers will be of significant benefit. Susanne worked until recently as Head of Application Technology for a Germany based, internationally renowned provider of laboratory products and services for the life science industry. Earlier in her career, she took responsibility as Manager Market & Business Intelligence of a leading international supplier of scientific analytical instruments in life sciences, medical & industry. Previous positions in her career included roles as Senior Market Manager for lab automation solutions, measuring equipment and diagnostics as well as Product Manager and Sales Representative for high-performance screening systems in pharmaceutical drug research. Susanne has a broad background from working in different internationally renowned companies in the field of Life Sciences, Medical Technology and Biotechnology. She holds a PhD in Neuroscience from the University of Tübingen and a Master of Science in Biology from the University of Kaiserslautern. The Executive Board welcomes Susanne to INFORS and wishes her every success in her career with the company.

Due to the development of COVID-19 / Corona many people are concerned. We would like to let you know how we are dealing with the situation. Our first priority is to protect the health and well-being of our employees, along with our customers, and to do our part to contain the virus. We follow global developments attentively, while implementing WHO recommendations consistently and with the utmost care. You can access our products and place your requests as usual at www.infors-ht.com. Even in these challenging times, we are happy to provide you with advice and solution-oriented support. Your contact person can be reached by e-mail or telephone at the usual times. You can also contact us via LinkedIn and Facebook. Take care and support each other. We firmly believe that we will get through the situation together.

With the Q3 2019 release, INFORS HT is changing the licenses for eve®, the platform software for bioprocesses. Instead of the Core, Plan & Control as well as User Management & Reporting packages, there are three licenses which can now be selected: Basic: Essential monitoring and reporting features for shaker and bioreactor experiments, perfect for smaller budgets. Standard: Workflow-oriented planning tools including comprehensive features for bioprocess automation, control, monitoring and reporting. Premium: Full version to meet the technical requirements of FDA 21 CFR Part 11 and EudraLex Annex 11. For customers, the new license structure offers an easier selection of the appropriate configuration and a simpler overview of the features. A new driver structure simplifies the connection of various third-party devices. Via a clearly arranged user interface, the user can define parameters which are monitored and controlled via eve®. The new drivers are available for OPC, Modbus and all Applikon bioreactors. Learn more about eve® and its features.

A second production line has been in operation since November in the Swiss headquarters in Bottmingen. In this way, INFORS HT is responding to the sustained high demand for its products. With the new production line, INFORS HT is doubling its capacities, which results in shorter delivery times. In Bottmingen, bioreactors and incubation shakers will be produced primarily for markets in Europe, Asia and Latin America. The USA and Canada are supplied by an additional production site of the U.S. branch which was also expanded in 2017.

With the Techfors, INFORS HT is offering a bespoke solution for production-scale bioprocesses. The new pilot bioreactor differs from its predecessors not only in terms of looks. The user interface is consistently workflow-oriented and therefore makes operating the Techfors absolute child's play. With the aid of the eve® bioprocess software, complex bioprocesses can not only be controlled, monitored and analyzed in a GMP-regulated environment, but also documented. As in the previous models, INFORS HT has implemented a modern design with clear lines. However, the new version of the pilot bioreactor has far much more to offer: "Besides the modern look with ergonomically arranged pumps and a tilting touch screen, we particularly focused on a consistently workflow-oriented user interface," explains Dr. Dirk Hebel, Lead Product Manager Bioreactors, INFORS HT. The result is a real eye-catcher. Controlling the new Techfors pilot bioreactor using the touch screen user interface is child's play. The software is the same as that used in the smaller bioreactors. The advantage of this is that the user can get started right away – without the need for any familiarization. The interface and procedures are already familiar from the smaller bench-top and parallel bioreactors. The eve® bioprocess software is used not only to control, monitor, and analyze complex bioprocesses but also to document them in conformity with GMP. The proven advantages of the Techfors are also offered by the new version: each pilot bioreactor is produced precisely according to the customer's requirements. Thanks to the modular design, sensors or analysis devices can be retrofitted at any time later on. The INFORS HT team is available as required to provide support during qualification and validation.

INFORS HT is releasing a new, even more powerful version of eve®. It includes better integration with hardware and software from third-party suppliers. Furthermore, a new alarm function is now available. This alerts the user via email if there are errors or values which deviate during the bioprocess. The latest eve® version, Q2 2019, makes it even easier to integrate devices and software from third-party manufacturers into the platform. The new email alarm goes beyond the previous control and monitoring via the browser. It notifies the user as soon as an alarm occurs in a specific batch. The parameters for this alarm, such as temperature deviations or network problems, can be specified in advance for each batch. Here is an overview of the most important features of the new eve® version: New automatic email alarm system: eve® sends you emails in the case of batch alarms Increased compatibility and flexibility with 3rd party devices and software: New REST API and new user interface for drivers to easily and quickly integrate additional devices and software to eve® The LIS (Liquid Injection System) shake flask feed pumps from aquila biolabs is now supported by eve® Additional features and optimizations: Improved overall performance when opening batches Automatic notification when a new version becomes available New SI units for parameters are available Designation of user-specified functions in the batch strategy Parameters can be renamed to allow adoption of the name(s) used by the connected device Customizable OPC (DA, XML DA and UA) drivers with new user interface Customizable Modbus (RTU and TCP) driver with new user interface Customizable Applikon drivers with new user interface The new version is available for free download to users with a valid Support & Assurance license.